Last 47 quarters of trend data · Healthcare · Medical - Instruments & Supplies
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | — | 18.45 | 20.71 | 22.47 | 28.87 | 25.00 | 22.57 | 24.43 | 28.92 | 24.17 | 24.27 | 30.29 | 24.81 | 35.02 | 34.65 | 34.01 | 38.16 | 39.40 | 49.69 | 47.53 | 47.40 |
| — | -26.2% | -8.2% | -8.0% | -0.2% | +3.4% | -7.0% | -19.3% | +16.6% | -31.0% | -30.0% | -10.9% | -35.0% | -11.1% | -30.3% | -28.5% | -19.5% | -15.0% | — | +10.0% | +34.9% | |
| P/S Ratio | 6.13 | 4.83 | 5.76 | 6.22 | 7.53 | 7.04 | 6.38 | 6.58 | 7.36 | 5.77 | 6.10 | 5.46 | 4.95 | 7.18 | 7.22 | 7.42 | 8.45 | 8.42 | 10.31 | 10.70 | 10.70 |
| — | -31.4% | -9.6% | -5.5% | +2.4% | +21.9% | +4.6% | +20.6% | +48.7% | -19.6% | -15.6% | -26.5% | -41.5% | -14.7% | -29.9% | -30.7% | -21.1% | -18.3% | +12.3% | +10.0% | +28.5% | |
| P/B Ratio | — | 4.29 | 5.08 | 5.60 | 6.58 | 6.36 | 5.94 | 6.43 | 6.94 | 5.81 | 6.31 | 5.66 | 5.13 | 7.81 | 8.21 | 8.21 | 9.36 | 9.17 | 10.87 | 12.18 | 12.79 |
| — | -32.5% | -14.4% | -12.8% | -5.2% | +9.5% | -5.8% | +13.5% | +35.2% | -25.6% | -23.2% | -31.0% | -45.2% | -14.9% | -24.5% | -32.6% | -26.8% | -26.8% | +4.3% | +12.1% | +36.8% | |
| P/FCF | 21.01 | 4.28 | 15.85 | 29.01 | 24.28 | 18.66 | 14.85 | 29.12 | 29.44 | 17.06 | 19.26 | 25.43 | 22.22 | 40.56 | 32.11 | 79.10 | 653.42 | 163.60 | 136.48 | 53.14 | — |
| — | -77.1% | +6.8% | -0.4% | -17.5% | +9.4% | -22.9% | +14.5% | +32.5% | -57.9% | -40.0% | -67.8% | -96.6% | -75.2% | -76.5% | +48.8% | — | +254.4% | +223.2% | -10.0% | — | |
| EV / EBITDA | 18.03 | 14.76 | 14.15 | 15.63 | 20.09 | 17.76 | 17.18 | 18.00 | 20.67 | 16.56 | 17.55 | 21.22 | 16.86 | 25.41 | 23.89 | 24.84 | 25.68 | 26.18 | 31.72 | 32.64 | 31.81 |
| — | -16.9% | -17.7% | -13.2% | -2.8% | +7.3% | -2.1% | -15.2% | +22.6% | -34.8% | -26.5% | -14.6% | -34.3% | -2.9% | -24.7% | -23.9% | -19.3% | -17.8% | +19.2% | +10.6% | +31.5% | |
| EV / EBIT | 18.03 | 14.56 | 15.64 | 17.36 | 21.79 | 20.51 | 19.67 | 20.13 | 23.43 | 23.47 | 19.32 | 19.57 | 19.98 | 29.34 | 28.08 | 28.04 | 29.78 | 30.79 | 38.71 | 39.15 | 37.59 |
| — | -29.0% | -20.5% | -13.8% | -7.0% | -12.6% | +1.8% | +2.9% | +17.3% | -20.0% | -31.2% | -30.2% | -32.9% | -4.7% | -27.4% | -28.4% | -20.8% | -18.7% | +19.8% | +13.3% | +26.3% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.1% | 58.8% | 62.2% | 62.2% | 61.5% | 60.8% | 59.3% | 58.6% | 58.6% | 57.6% | 56.9% | 57.6% | 54.4% | 55.0% | 55.3% | 56.1% | 56.9% | 57.1% | 56.8% | 56.4% | 56.0% |
| — | -3.3% | +4.9% | +6.1% | +4.9% | +5.7% | +4.2% | +1.8% | +7.6% | +4.6% | +3.0% | +2.7% | -4.3% | -3.7% | -2.7% | -0.5% | +1.6% | +2.0% | -2.3% | -2.5% | -4.0% | |
| Operating Margin | 33.4% | 30.7% | 34.9% | 35.0% | 33.4% | 33.7% | 33.0% | 32.5% | 31.6% | 31.2% | 31.3% | 23.7% | 26.2% | 24.5% | 26.9% | 27.1% | 29.0% | 27.9% | 27.1% | 27.8% | 29.0% |
| — | -9.1% | +5.8% | +7.5% | +5.7% | +8.2% | +5.4% | +37.6% | +20.6% | +27.0% | +16.2% | -12.7% | -9.6% | -12.1% | -0.7% | -2.5% | +0.2% | +1.2% | -6.8% | +0.3% | +0.4% | |
| Net Margin | 26.9% | 26.2% | 27.9% | 27.6% | 26.1% | 28.2% | 28.3% | 26.9% | 25.4% | 23.9% | 25.1% | 18.0% | 19.9% | 20.5% | 20.8% | 21.8% | 22.1% | 21.3% | 20.7% | 22.5% | 22.5% |
| — | -7.0% | -1.4% | +2.7% | +2.6% | +17.9% | +12.6% | +49.7% | +27.7% | +16.7% | +20.6% | -17.5% | -10.1% | -4.0% | +0.5% | -3.5% | -1.7% | -4.2% | +302.8% | +0.5% | -5.1% |
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 24.3% | 5.9% | 6.2% | 6.3% | 5.8% | 6.6% | 6.8% | 6.6% | 6.2% | 6.2% | 6.6% | 4.8% | 5.2% | 5.7% | 6.1% | 6.3% | 6.2% | 5.9% | 5.6% | 6.5% | 6.9% |
| — | -11.1% | -7.9% | -4.3% | -6.9% | +7.1% | +2.5% | +37.9% | +18.2% | +8.1% | +8.8% | -23.8% | -15.5% | -3.0% | +8.8% | -4.1% | -10.0% | -15.7% | +297.9% | +0.9% | -0.1% | |
| ROA | 17.8% | 4.3% | 4.6% | 4.7% | 4.2% | 4.8% | 5.0% | 4.8% | 4.4% | 4.3% | 4.4% | 3.1% | 3.3% | 3.4% | 3.5% | 3.8% | 4.1% | 3.9% | 3.7% | 4.3% | 4.3% |
| — | -10.4% | -7.1% | -2.7% | -4.3% | +13.0% | +13.3% | +56.8% | +35.8% | +25.2% | +26.1% | -19.4% | -20.6% | -12.6% | -6.5% | -11.0% | -4.8% | -6.9% | +316.7% | +9.2% | +11.1% | |
| ROIC | 24.5% | 5.8% | 6.5% | 6.5% | 6.0% | 6.2% | 5.8% | 5.6% | 5.2% | 5.2% | 5.0% | 3.7% | 3.9% | 3.8% | 4.2% | 4.4% | 5.1% | 4.8% | 4.6% | 5.0% | 5.5% |
| — | -6.0% | +11.6% | +16.1% | +14.5% | +19.2% | +15.8% | +51.8% | +32.8% | +36.6% | +20.5% | -16.0% | -22.4% | -21.8% | -9.0% | -11.9% | -8.6% | -10.1% | -5.7% | +5.2% | +15.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.13 | 0.13 | 0.13 | 0.16 | 0.14 | 0.14 | 0.15 | 0.16 | 0.16 | 0.18 | 0.25 | 0.31 | 0.35 | 0.38 | 0.44 | 0.52 | 0.27 | 0.27 | 0.25 | 0.27 | 0.31 |
| — | -12.1% | -14.2% | -0.9% | -15.5% | -20.6% | -40.0% | -48.5% | -53.5% | -53.0% | -42.5% | -40.2% | +29.8% | +40.1% | +72.8% | +95.0% | -13.7% | -0.7% | -20.9% | -21.1% | -29.3% | |
| Debt / EBITDA | 0.44 | 1.77 | 1.48 | 1.79 | 1.71 | 1.61 | 1.76 | 1.77 | 1.93 | 2.00 | 2.72 | 4.45 | 4.37 | 4.78 | 4.88 | 5.95 | 2.91 | 3.05 | 2.91 | 2.81 | 3.07 |
| — | +9.7% | -15.6% | +0.8% | -11.2% | -19.6% | -35.4% | -60.1% | -55.9% | -58.1% | -44.2% | -25.3% | +50.1% | +56.5% | +67.6% | +112.2% | -5.2% | +10.6% | -9.1% | -21.6% | -31.1% | |
| Current Ratio | 3.10 | 3.10 | 3.01 | 3.06 | 2.89 | 3.44 | 3.41 | 3.33 | 2.92 | 2.59 | 3.04 | 3.11 | 2.99 | 3.12 | 3.07 | 3.17 | 2.94 | 2.80 | 2.55 | 2.49 | 2.54 |
| — | -9.9% | -11.8% | -8.1% | -1.1% | +32.9% | +12.2% | +7.0% | -2.3% | -17.1% | -0.9% | -1.9% | +1.8% | +11.4% | +20.2% | +27.4% | +15.5% | +62.2% | +52.7% | -0.9% | -2.7% | |
| Quick Ratio | 2.42 | 2.42 | 2.33 | 2.32 | 2.13 | 2.53 | 2.49 | 2.29 | 1.91 | 1.69 | 1.97 | 1.63 | 1.75 | 1.81 | 1.74 | 1.82 | 1.69 | 1.72 | 1.56 | 1.54 | 1.73 |
| — | -4.3% | -6.5% | +1.2% | +12.0% | +50.0% | +26.7% | +40.4% | +9.1% | -6.6% | +13.0% | -10.4% | +3.5% | +4.8% | +11.8% | +18.6% | -2.4% | +40.5% | +39.0% | -9.1% | -4.0% | |
| Interest Coverage | 37.80 | — | 41.88 | 63.42 | 51.81 | — | 131.23 | 88.37 | 70.70 | 32.21 | 27.11 | 24.58 | 19.32 | 19.16 | 20.09 | 27.92 | 38.65 | 46.08 | 42.89 | 41.81 | 48.86 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RMD stock.
ResMed Inc.'s current operating margin is 33.4%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking ResMed Inc.'s business trajectory between earnings reports.